Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanofi Genzyme
Top 10 Things To Watch For At DDW
At Digestive Disease Week, Celltrion will seek to strengthen its hold on the IBD market, Ironwood hopes to expand Linzess into pediatric functional constipation, and competitors will showcase competing short bowel syndrome treatment and colorectal cancer companion diagnostics.
Next Allergy Blockbuster? GI Innovation Shares Why It Is Confident
GI Innovation chairman and CEO B G Rhee talks about his ambitions for the Korean bispecific protein firm’s leading allergy and immuno-oncology pipeline assets and what is behind his confidence.
Bold Plans Pivotal GI Cancer Studies After Phase II Success
The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.
Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns
Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.
- Other Names / Subsidiaries
- ILEX Oncology, Inc.
- Sangstat Medical Corporation
- Genzyme Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.